title: Response to 'Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 studies has not been Justified and on Balance is Not Useful' by D.A. Parasrampuria and L.Z. Benet.
authors.affiliation: Horizon Pharma, Brisbane, CA, USA. jganju@yahoo.com.
authors.forename: Jitendra
authors.initials: J
authors.lastname: Ganju
authors.affiliation: Johnson and Johnson, New Brunswick, NJ, USA.
authors.forename: Clapton
authors.initials: C
authors.lastname: Dias
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D006801:Humans; D015990:Placebo Effect; D012107:Research Design